ClinicalTrials.gg
Active, not recruitingNCT06097975NEO-GLITIPNIUpdated Oct 2, 2026

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

A Phase 1 interventional study of Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV and Neurosurgery and intracavitary injection nivolumab and ipililumab in Recurrent Glioblastoma, sponsored by Universitair Ziekenhuis Brussel. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Universitair Ziekenhuis Brussel · Phase 1, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 2, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Glioblastoma with a site in Belgium — 14 open to participants now, 20 under way, 3 of them phase 3. Glioblastoma · Belgium.

Planned enrollment
47th of 51
18 · median 110
Started
2024
with 3 others
Phase 1
8 of 58
1 open now
Primary completion
2027-06
later than 10 of 19 live
Registered
48th of 58
by date
Lead sponsor
3 of 58
Universitair Ziekenhuis Brussel

Among the 58 studies in Glioblastoma with a site in Belgium, this one is the 47th largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 10 of the 19 other live ones, and was the 48th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

14 of the 58 studies in Glioblastoma with a site in Belgium are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Glioblastoma with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma.

Participants will:

  • receive neo-adjuvant administration of intravenous immunotherapy
  • followed by a maximal safe neurosurgical resection
  • afterwards, immunotherapy will be injected into the brain tissue
  • followed by insertion of an Ommaya reservoir
  • postoperatively, administration of immunotherapy will be continued
03

Conditions studied

  • Recurrent Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Subjects must have signed and dated an approved written form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
  2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor , and other requirements of the study.
  3. Histopathological diagnosis of glioblastoma (= IDHwt, WHO grade IV astrocytoma of the central nervous system (Louis, Perry et al. 2021).
  4. Diagnosis of resectable glioblastoma recurrence and/or progression following prior standard of care treatment (surgery for resectable lesions, radiation therapy and temozolomide chemotherapy). Recurrence/progression is defined as significant [according to the investigators assessment] growth and/or recurrence of the glioblastoma tumor mass on sequential MRI of the brain;
  5. The following disease characteristics should be present:

    1. Presence of a measurable tumor lesion that is characterized by gadolinium enhancement on T1-MRI of the brain (with a longest diameter of > 10 mm and a perpendicular diameter of >5mm).
    2. No evidence of spontaneous intra-tumor hemorrhage on baseline MRI-imaging or in the prior disease history;
  6. No ventriculo-peritoneal drain:
  7. No for evaluation by gadolinium enhanced MRI, 18FFET-PET/CT of the brain or whole-body contrast enhanced CT;
  8. performance status score of 0, 1 or 2;
  9. An interval of at least 4 months (: 16 weeks) after the end of postoperative radiation therapy for glioblastoma unless progression is confirmed on an MRI of the brain obtained > 4 week after the first observation of progression; and with an interval of at least 4 weeks after the last administration of temozolomide;
  10. Male or female, 18 years of age or older;
  11. Resolution of all acute treatment related adverse effects of prior surgical procedures, radiotherapy and temozolomide to NCI CTCAEv4.0 grade 0 or 1 except for alopecia;
  12. Adequate organ function as defined by the following criteria:

    1. Total serum \< 1.5 x (patients with Gilbert's disease exempt who should have bilirubin \< 2x ULN)
    2. and ALT \< 2.5 x upper limit of normal (ULN);
    3. Serum creatinine ≤1.5 x ULN or calculated ≥60 mL/min
    4. (ANC) > 1500/mm³ without growth factor support
    5. > 75 000 cells/mm³
    6. ≥9 g/dL (which may be obtained by transfusion or growth factor support)
    7. FT4 hormone levels within normal range;
  13. No prior treatment on a nivolumab and/or ipilimumab trial;
  14. No prior treatment with an or anti-PD-1/-L1 targeted therapy;
  15. No gastrointestinal abnormalities including:

    1. Inability to take oral medication.
    2. Requirement for intravenous alimentation.
    3. Prior surgical procedures affecting absorption including gastric resection.
    4. Treatment for active peptic ulcer disease in the past 6 months.
    5. Malabsorption syndromes.
    6. Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
  16. No evidence of pre-existing uncontrolled hypertension as documented by baseline blood pressure reading. The baseline systolic blood pressure reading must be ≤140 mm Hg, and the baseline diastolic blood pressure readings must be ≤90 mm Hg. If baseline blood pressure reading exceeds the inclusion values a second blood pressure reading (taken at least 1 hour apart) must be documented in order to confirm the absence of uncontrolled hypertension. Patients whose hypertension is controlled by antihypertensive therapies are eligible;
  17. No concurrent treatment:

    1. In another therapeutic clinical trial;
    2. No requirement for permanent therapeutic anticoagulation therapy.
  18. Subjects with active, known, or suspected disease are not eligible. Subjects with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll;
  19. Subjects requiring systemic treatment with either (> 8 mg daily methylprednisolone equivalent) or other medications within 14 days of study enrollment. Inhaled or topical steroids are permitted in the absence of active autoimmune disease;
  20. No active uncontrolled seizure disorder;
  21. No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure or any unstable arrhythmia, cerebrovascular accident or , within the 12 months prior to study drug administration.;
  22. No known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness;
  23. No serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment;
  24. No history of a (other than glioma) except those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years;
  25. No other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study;
  26. No dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol;
  27. Female patients must be surgically sterile or be , or must agree to use effective measures during the period of therapy, which should be continued for at least 5 months following the last dose of nivolumab as indicated in the SmPC. All female patients with must have a negative pregnancy test (serum or urine) prior to enrollment and pregnancy testing should be conducted within 24h prior to the first dose of immune checkpoint inhibitors and thereafter monthly and at the end of systemic exposure. The definition of effective contraception will be included in the Informed consent form. Women must not be breastfeeding at initiation of screening.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Drug: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV · Procedure: Neurosurgery and intracavitary injection nivolumab and ipililumab · Drug: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary

Interventions

  • DrugNeo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV

    Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.

  • ProcedureNeurosurgery and intracavitary injection nivolumab and ipililumab

    The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir

  • DrugAdjuvant nivolumab IV + nivolumab and ipililumab intracavitary

    Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable recurrent glioblastoma.

    Incidence of treatment related adverse events (TRAE). TRAE will be collected on a continuous basis. Type, frequency and severity (graded according to the CTCAEv5) will be reported descriptively.

    Time frame: 1 year

Secondary outcomes

  1. Estimate anti-tumor responses of the proposed investigational (neo-)adjuvant treatment regimen.

    Objective response rate (ORR, according to iRANO criteria) following 4 weeks of neo-adjuvant therapy.

    Time frame: 4 years

Other outcomes

  1. Estimate progression-free and overall survival estimated by Kaplan-Meier survival estimates.

    PFS and OS estimated by Kaplan-Meier survival analysis (incl. median, 6-months-, and yearly survival rates with 95% CI).

    Time frame: 4 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 38 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jun 2025 → Jun 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 24, 2023
StartActual
Mar 15, 2024
Primary completionEst.
Jun 1, 2027was Jun 2025
CompletionEst.
Dec 1, 2027was Dec 2025
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Sites
1 site added, 1 site removed
Show site
  • UZ Brussel · Brussels, Belgium
Show 1 removed
  • UZ Brussel · Brussels, Belgium
Oct 2, 2026
Primary completion
Jun 1, 2025→Jun 1, 2027
Oct 2, 2026
Study completion
Dec 1, 2025→Dec 1, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • UZ Brussel · Brussels, Belgium
    Show 1 removed
    • UZ Brussel · Brussels, Belgium
    Primary completion Jun 1, 2025→Jun 1, 2027
    Study completion Dec 1, 2025→Dec 1, 2027
    + 4 other changes: index terms, verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06097975
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Mar 15, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion